08:09 AM EDT, 10/20/2025 (MT Newswires) -- Clearmind Medicine ( CMND ) said Monday that a US patent application has been published by the US Patent and Trademark Office for its innovative combination therapy of 5-methoxy-2-aminoindane and N-Acylethanolamines, such as Palmitoylethanolamide, targeting binge behavior disorders.

The clinical-stage biotech company said this patent application stems from its ongoing collaboration with SciSparc ( SPRC ) , and that this therapy targets multiple binge behaviors, including excessive alcohol consumption binge eating, smoking, compulsive shopping, and problematic sexual conduct.

Clearmind Medicine ( CMND ) shares were up less than 1% in recent Monday premarket activity, while SciSparc's ( SPRC ) were up 23%.